Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Equity Average (2019 - 2026)

InMed Pharmaceuticals has reported Equity Average over the past 5 years, most recently at $10.6 million for Q4 2025.

  • For Q4 2025, Equity Average rose 45.28% year-over-year to $10.6 million; the TTM value through Dec 2025 reached $10.6 million, up 45.28%, while the annual FY2025 figure was $11.3 million, 6.31% up from the prior year.
  • Equity Average for Q4 2025 was $10.6 million at InMed Pharmaceuticals, down from $12.5 million in the prior quarter.
  • Over five years, Equity Average peaked at $14.7 million in Q4 2021 and troughed at $1.3 million in Q3 2023.
  • A 5-year average of $9.9 million and a median of $10.4 million in 2025 define the central range for Equity Average.
  • Biggest five-year swings in Equity Average: plummeted 87.5% in 2023 and later skyrocketed 600.8% in 2024.
  • Year by year, Equity Average stood at $14.7 million in 2021, then decreased by 13.77% to $12.7 million in 2022, then tumbled by 87.4% to $1.6 million in 2023, then soared by 356.39% to $7.3 million in 2024, then surged by 45.28% to $10.6 million in 2025.
  • Business Quant data shows Equity Average for INM at $10.6 million in Q4 2025, $12.5 million in Q3 2025, and $10.2 million in Q2 2025.